Rhythm says setmelanotide cuts BMI 16.9% at 12 months in acquired hypothalamic obesity study

• Rhythm Pharmaceuticals flagged new real-world analyses and Phase 3 post hoc results for setmelanotide in acquired hypothalamic obesity, presented at European Congress of Endocrinology in May 2026.
• Real-world early-access experience in France showed sustained weight loss with improvements in patient-reported hunger, supporting effectiveness outside controlled trials.
• Separate Phase 3 analyses indicated broader cardiometabolic risk improvements versus placebo, extending treatment impact beyond weight reduction.
• Additional research in Bardet-Biedl syndrome suggested severe hyperphagia is frequently under-recognized when assessed only by self-reported questionnaires, pointing to a measurement gap that could affect diagnosis and care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120800PRIMZONEFULLFEED9717976) on May 12, 2026, and is solely responsible for the information contained therein.